Nav: Home

Treatment relieves depression in 90% of participants in small study

April 07, 2020

A new form of magnetic brain stimulation rapidly relieved symptoms of severe depression in 90% of participants in a small study conducted by researchers at the Stanford University School of Medicine.

The researchers are conducting a larger, double-blinded trial in which half the participants are receiving fake treatment. The researchers are optimistic the second trial will prove to be similarly effective in treating people whose condition hasn't improved with medication, talk therapy or other forms of electromagnetic stimulation.

The treatment is called Stanford Accelerated Intelligent Neuromodulation Therapy, or SAINT. It is a form of transcranial magnetic stimulation, which is approved by the Food and Drug Administration for treatment of depression. The researchers reported that the therapy improves on current FDA-approved protocols by increasing the number of magnetic pulses, speeding up the pace of the treatment and targeting the pulses according to each individual's neurocircuitry.

Before undergoing the therapy, all 21 study participants were severely depressed, according to several diagnostic tests for depression. Afterward, 19 of them scored within the nondepressed range. Although all of the participants had suicidal thoughts before the therapy, none of them reported having suicidal thoughts after treatment. All 21 participants had previously not experienced improvements with medications, FDA-approved transcranial magnetic stimulation or electroconvulsive therapy.

The only side effects of the new therapy were fatigue and some discomfort during treatment, the study reported. The results will be published online April 6 in the American Journal of Psychiatry.

"There's never been a therapy for treatment-resistant depression that's broken 55% remission rates in open-label testing," said Nolan Williams, MD, assistant professor of psychiatry and behavioral sciences and a senior author of the study. "Electroconvulsive therapy is thought to be the gold standard, but it has only an average 48% remission rate in treatment-resistant depression. No one expected these kinds of results."

Calming the brain chatter

When Deirdre Lehman, 60, woke up the morning of June 30, 2018, she said she was hit by "a tsunami of darkness." Lehman had struggled with bipolar disorder all her adult life, but with medications and psychotherapy her mood had been stable for 15 years.

"There was a constant chattering in my brain: It was my own voice talking about depression, agony, hopelessness," she said. "I told my husband, 'I'm going down and I'm heading toward suicide.' There seemed to be no other option."

Lehman's psychiatrist had heard of the SAINT study and referred her to Stanford. After researchers pinpointed the spot in her brain that would benefit from stimulation, Lehman underwent the therapy.

"By the third round, the chatter started to ease," she said. "By lunch, I could look my husband in the eye. With each session, the chatter got less and less until it was completely quiet.

"That was the most peace there's been in my brain since I was 16 and started down the path to bipolar disorder."

In transcranial magnetic stimulation, electric currents from a magnetic coil placed on the scalp excite a region of the brain implicated in depression. The treatment, as approved by the FDA, requires six weeks of once-daily sessions. Only about half of patients who undergo this treatment improve, and only about a third experience remission from depression.

Stanford researchers hypothesized that some modifications to transcranial magnetic stimulation could improve its effectiveness. Studies had suggested that a stronger dose, of 1,800 pulses per session instead of 600, would be more effective. The researchers were cautiously optimistic of the safety of the treatment, as that dose of stimulation had been used without harm in other forms of brain stimulation for neurological disorders, such as Parkinson's disease.

Other studies suggested that accelerating the treatment would help relieve patients' depression more rapidly. With SAINT, study participants underwent 10 sessions per day of 10-minute treatments, with 50-minute breaks in between. After a day of therapy, Lehman's mood score indicated she was no longer depressed; it took up to five days for other participants. On average, three days of the therapy were enough for participants to have relief from depression.

"The less treatment-resistant participants are, the longer the treatment lasts," said postdoctoral scholar Eleanor Cole, PhD, a lead author of the study.

Strengthening a weak connection

The researchers also conjectured that targeting the stimulation more precisely would improve the treatment's effectiveness. In transcranial magnetic stimulation, the treatment is aimed at the location where most people's dorsolateral prefrontal cortex lies. This region regulates executive functions, such as selecting appropriate memories and inhibiting inappropriate responses.

For SAINT, the researchers used magnetic-resonance imaging of brain activity to locate not only the dorsolateral prefrontal cortex, but a particular subregion within it. They pinpointed the subregion in each participant that has a relationship with the subgenual cingulate, a part of brain that is overactive in people experiencing depression.

In people who are depressed, the connection between the two regions is weak, and the subgenual cingulate becomes overactive, said Keith Sudheimer, PhD, clinical assistant professor of psychiatry and a senior author of the study. Stimulating the subregion of the dorsolateral prefrontal cortex reduces activity in the subgenual cingulate, he said.

To test safety, the researchers evaluated the participants' cognitive function before and after treatment. They found no negative side effects; in fact, they discovered that the participants' ability to switch between mental tasks and to solve problems had improved -- a typical outcome for people who are no longer depressed.

One month after the therapy, 60% of participants were still in remission from depression. Follow-up studies are underway to determine the duration of the antidepressant effects.

The researchers plan to study the effectiveness of SAINT on other conditions, such as obsessive-compulsive disorder, addiction and autism spectrum disorders.

'Resilient and stable'

The depression Lehman woke up to almost two years ago was the worst episode she had ever experienced. Today, she said, she is happy and calm.

Since undergoing SAINT treatment, she has completed a bachelor's degree at the University of California-Santa Barbara; she had dropped out as a young woman when her bipolar symptoms overwhelmed her studies.

"I used to cry over the slightest thing," she said. "But when bad things happen now, I'm just resilient and stable. I'm in a much more peaceful state of mind, able to enjoy the positive things in life with the energy to get things done."
-end-
Graduate student Katy Stimpson and Brandon Bentzley, MD, PhD, a medical fellow in psychiatry and behavioral sciences, are also lead authors.

Other Stanford co-authors are former lab manager Merve Gulser; graduate students Kirsten Cherian, Elizabeth Choi, Haley Aaron and Austin Guerra; Flint Espil, PhD, clinical assistant professor of psychiatry and behavioral sciences; research coordinators Claudia Tischler, Romina Nejad and Heather Pankow; medical student Jaspreet Pannu; postdoctoral scholars Xiaoqian Xiao, PhD, James Bishop, PhD, John Coetze, PhD, and Angela Phillips, PhD; Hugh Solvason, MD, PhD, clinical professor of psychiatry and behavioral sciences; research manager Jessica Hawkins; Booil Jo, PhD, associate professor of psychiatry and behavioral sciences; Kristin Raj, MD, clinical assistant professor of psychiatry and behavioral sciences; Charles DeBattista, MD, professor of psychiatry and behavioral sciences; Jennifer Keller, PhD, clinical associate professor of psychiatry and behavioral sciences; and Alan Schatzberg, MD, professor of psychiatry and behavioral sciences.

The research was supported by Charles R. Schwab, the Marshall and Dee Ann Payne Fund, the Lehman Family Neuromodulation Research Fund, the Still Charitable Fund, the Avy L. and Robert L. Miller Foundation, a Stanford Psychiatry Chairman's Small Grant, the Stanford CNI Innovation Award, the National Institutes of Health (grants T32035165 and UL1TR001085), the Stanford Medical Scholars Research Scholarship, the NARSAD Young Investigator Award and the Gordie Brookstone Fund.

The Stanford University School of Medicine consistently ranks among the nation's top medical schools, integrating research, medical education, patient care and community service. For more news about the school, please visit http://med.stanford.edu/school.html. The medical school is part of Stanford Medicine, which includes Stanford Health Care and Stanford Children's Health. For information about all three, please visit http://med.stanford.edu.

Print media contact: Mandy Erickson at (650) 736-0264 (merickso@stanford.edu)
Broadcast media contact: Margarita Gallardo at (650) 723-7897 (mjgallardo@stanford.edu)

Stanford Medicine

Related Depression Articles:

Children with social anxiety, maternal history of depression more likely to develop depression
Although researchers have known for decades that depression runs in families, new research from Binghamton University, State University of New York, suggests that children suffering from social anxiety may be at particular risk for depression in the future.
Depression and use of marijuana among US adults
This study examined the association of depression with cannabis use among US adults and the trends for this association from 2005 to 2016.
Maternal depression increases odds of depression in offspring, study shows
Depression in mothers during and after pregnancy increased the odds of depression in offspring during adolescence and adulthood by 70%.
Targeting depression: Researchers ID symptom-specific targets for treatment of depression
For the first time, physician-scientists at Beth Israel Deaconess Medical Center have identified two clusters of depressive symptoms that responded to two distinct neuroanatomical treatment targets in patients who underwent transcranial magnetic brain stimulation (TMS) for treatment of depression.
A biological mechanism for depression
Researchers report that in depressed individuals there are increased amounts of an unmodified structural protein, called tubulin, in lipid rafts compared with non-depressed individuals.
Depression in adults who are overweight or obese
In an analysis of primary care records of 519,513 UK adults who were overweight or obese between 2000-2016 and followed up until 2019, the incidence of new cases of depression was 92 per 10,000 people per year.
Why stress doesn't always cause depression
Rats susceptible to anhedonia, a core symptom of depression, possess more serotonin neurons after being exposed to chronic stress, but the effect can be reversed through amygdala activation, according to new research in JNeurosci.
Which comes first: Smartphone dependency or depression?
New research suggests a person's reliance on his or her smartphone predicts greater loneliness and depressive symptoms, as opposed to the other way around.
Depression breakthrough
Major depressive disorder -- referred to colloquially as the 'black dog' -- has been identified as a genetic cause for 20 distinct diseases, providing vital information to help detect and manage high rates of physical illnesses in people diagnosed with depression.
CPAP provides relief from depression
Researchers have found that continuous positive airway pressure (CPAP) treatment of obstructive sleep apnea (OSA) can improve depression symptoms in patients suffering from cardiovascular diseases.
More Depression News and Depression Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Sound And Silence
Sound surrounds us, from cacophony even to silence. But depending on how we hear, the world can be a different auditory experience for each of us. This hour, TED speakers explore the science of sound. Guests on the show include NPR All Things Considered host Mary Louise Kelly, neuroscientist Jim Hudspeth, writer Rebecca Knill, and sound designer Dallas Taylor.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

Kittens Kick The Giggly Blue Robot All Summer
With the recent passing of Ruth Bader Ginsburg, there's been a lot of debate about how much power the Supreme Court should really have. We think of the Supreme Court justices as all-powerful beings, issuing momentous rulings from on high. But they haven't always been so, you know, supreme. On this episode, we go all the way back to the case that, in a lot of ways, started it all.  Support Radiolab by becoming a member today at Radiolab.org/donate.